Histone dependent signalization during pharmacotherapy of chronic obstructive pulmonary disease;Sygnalizacja zależna od histonów w farmakoterapii przewlektej obturacyjnej choroby ptuc

Pneumonologia i Alergologia Polska

Volumn 75, Issue 4, 2007, Pages 375-382

  Mróz, Robert Marek ^a,c   Noparlik, Jacek ^b   Chyczewska, Elzbieta ^a   Braszko, Jan Józef ^b   Hołownia, Adam ^b  

^a Akademii Medycznej W Biatymstoku

^b Akademii Medycznej w Biatymstoku

^c MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

COPD; Corticosteroids; HDAC; Histones; N acetylcysteine; Theophyline

Indexed keywords

ACETYLCYSTEINE; ANTIINFLAMMATORY AGENT; CORTICOSTEROID; HISTONE; THEOPHYLLINE;

ANIMAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFECT; HUMAN; METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW;

ACETYLCYSTEINE; ADRENAL CORTEX HORMONES; ANIMALS; ANTI-INFLAMMATORY AGENTS; HISTONES; HUMANS; OXIDATIVE STRESS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; THEOPHYLLINE;

EID: 38149136591     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Kozielski J., Chazan R., Gorecka D. i wsp. Diagnosis and therapy of chronic obstructive pulmonary disease-recommendations of the Polish Phtisiopneumonology Society. Pneumonol. Alergol. Pol. 2002; 70 (supl. 2): 2-42.
2. Gorecka D., Zielinski J. Early diagnosis and prevention of COPD in Poland; current status and perspectives. Pneumonol. Alergol. Pol. 2005; 73: 112-115.
3. Vollmer W.M. Epidemiology of COPD: Overview and the US perspective. Eur. Respir. J. 2003; 22 (supl. 43): 1-44.
4. Barnes P.J. Mediators of chronic obstructive pulmonary disease. Pharm. Rev. 2004; 56: 515-548.
5. Barnes P.J., Chung K.F., Page C.P. Inflammatory mediators of asthma: an update. Pharm. Rev. 1998; 50: 515-596.
6. Hart L.A., Krishnan V.L., Adcock I.M., Barnes P.J., Chung K.F. Activation and localization of transcription factor κB in asthma. Am. J. Respir. Crit. Care Med. 1998; 158: 1585-1592.
7. Di Stefano A., Caramori G., Oates T. i wsp. Increased expression of NK-κB in bronchial biopsies from smokers and patient with COPD. Eur. Respir, J. 2002; 20: 556-563.
8. Muller-Ladner U., Gay R.E., Gay S. Role of nuclear factor κB in synovial inflammation. Curr. Rheumatol. Rep. 2002; 4: 201-207.
9. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997; 389: 349-352.
10. Littau V.C., Burdick C.J., Allfrey V.G., Mirsky S.A. The role of histones in the maintenance of chromatin structure. Proc. Natl, Acad. Sci. USA. 1965; 54: 1204-1212.
11. Ogryzko V.V., Schlitz R.L., Russanova V., Howard B.H., Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996; 87: 953-959.
12. Urnov F.D., Wolffe A.P. Chromatin remodeling and transcriptional activation: the cast (in order of appearance). Oncogene 2001; 20: 2991-3006.
13. Roth S.Y., Denu J.M., Allis C.D. Histone acetyltransferases. Annu. Rev. Biochem. 2001; 70: 81-120.
14. Ito K., Barnes P.J., Adcock I.M, Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits IL-lb-induced histone H4 acetylation on lysines 8 and 12. Mol. Cell. Biol. 2000; 20: 6891-6903.
15. Ito K., Ito M., Elliott W.M. i wsp. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N. Engl. J. Med. 2005; 352: 1967-1976.
16. Thiagalingam S., Cheng K.H., Lee H.J. i wsp. Histone deacetylases: unique players in shaping the epigenetic histone code, Ann. N. Y. Acad. Sci. 2003; 983: 84-100.
17. Cohen H.Y., Miller C. Bitterman K.J. i wsp. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004; 305: 390-392.
18. Buck S.W., Gallo C.M., Smith J.S. Diversity in the Sir2 family of protein deacetylases. J. Leukoc. Biol. 2004; 75: 939-950.
19. Yeung F., Hoberg J.E., Ramsey C.S. i wsp. Modulation of NF-kappaB dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004; 23: 2369-2380.
20. Privalsky M.L. The role of corepressors in transcriptional regulation by nuclear hormone receptors. Ann. Rev. Physiol. 2004; 66: 315-360.
21. Ashburner B.P., Westerheide S.D., Baldwin A.S., JR. The p65 (RelA) subunit of NF-κB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol. Cell Biol. 2001; 21: 7065-7077.
22. Chen L., Fischle W., Verdin E., Greene W.C., Duration of nuclear NF-κB action regulated by reversible acetylation. Science 2001; 293: 1653-1657.
23. Zhong H., May M.J., Jimi E., Ghosh S. The phosphorylation status of nuclear NF-κB determines its association with CBP//p300 or HDAC-1. Mol. Cell. 2002; 9: 625-636.
24. Ito K., Ito M., Elliott W.M. i wsp. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N. Engl. J. Med. 2005; 352:1967-1976.
25. Ito K., Lim S., Caramori G., Chung K.F., Barnes P.J., Adcock I.M. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression and inhibits glucocorticoid actions in alveolar macrophages. FASEB J. 2001; 15: 1100-1102.
26. Montuschi P., Collins J.V., Ciabattoni G. i wsp. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am. J. Respir. Crit. Care Med. 2000; 162: 1175-1177.
27. Bowler R.P., Barnes P.J., Crapo J.D. The role of oxidative stress in chronic obstructive pulmonary disease, J. COPD. 2004; 2: 255-277.
28. Moodie F.M., Marwick J.A., Anderson C.S. i wsp. Oxidative stress and cigarette smoke alter chromatin remodeling but differentially regulate NFκB activation and proinflammatory cytokine release in alveolar epithelial cells. FASEB J. 2004; 18: 1897-1899.
29. Paredi P., Kharitonov S.A., Leak D., Ward S., Cramer D., Barnes P.J. Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 162: 369-373.
30. Montuschi P., Collins J.V., Ciabattoni G. i wsp. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am. J. Respir. Crit. Care Med. 2000; 162: 1175-1177.
31. Biernacki W.A., Kharitonov S.A., Barnes P.J. Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax 2003; 58: 294-298.
32. Rahman I., van Schadewijk A.A., Crowther A.J. i wsp. 4-Hydroxy-2-nonenal, a specific lipid peroxidation product, is elevated in lungs of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002; 166: 490-495.
33. Higashimoto Y., Elliott W.M., Behzad A.R. i wsp. Inflammatory mediator mRNA expression by adenovirus ElA transfected bronchial epithelial cells, Am. J. Respir. Crit. Care Med. 2002; 166: 200-207.
34. Retamales I., Elliott W.M., Meshi B. i wsp. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am. J. Respir. Crit. Care Med. 2001; 164: 469-473.
35. Hogg J.C. Role of latent viral infections in chronic obstructive pulmonary disease and asthma. Am. J. Respir, Crit. Care Med. 2001; 164: S71-S75.
36. Fletcher C.M., Peto R., Tinker C.M., Spizer F.E. The Natural History of Chronic Bronchitis and Emphysema, Oxford University Press, 1976.
37. Barnes P.J., Stockley R.A. COPD: current therapeutic interventions and future approaches. Eur. Resp. J. 2005; 25: 1084-1106.
38. Alsaeedi A., Sinn D.D., McAlister F.A. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systemic review of randomized placebo controDed trials, Am. J. Med. 2002; 113: 59-65.
39. Keatings V.M, Jatakanon A., Worsdell Y.M., Barnes P.J. Effects of inhaled and oral glucocorticosteroids on inflammatory indices in asthma and COPD. Am. J. Respir. Crit. Care Med. 1997; 155: 542-548.
40. Hogg J.C. The nature of small-airway obstruction in chronic obstructive pulmonary disease. New Engl. J. Med. 2004; 350: 2645-2653.
41. Barnes P.J. Corticosteroids: The drugs to beat European Journal of Pharmacology 2006; 533: 2-14.
42. Barnes P.J., Adcock I.M. Transcription factors and asthma. Eur. Respir. J. 1998; 12: 221-234.
43. Barnes P.J., Karin M. Nuclear factor κB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 1997; 336: 1066-1071.
44. Wu B., Li P., Liu Y. i wsp. 3D structure of human FK506-binding protein 52: implications for the assembly of the glucocorticoid receptor/Hsp90/ immunophilln heterocomplex. Proc. Natl. Acad. Sci. U.S.A. 2004; 101: 8348-8353.
45. Hart L., Lim S., Adcock I., Barnes P.J., Chung K.F. Effects of inhaled corticosteroid therapy on expression and DMA-binding activity of nuclear factor-kB in asthma. Am. J. Respir. Crit. Care Med. 2000; 161: 224-231.
46. Pujols L., Mullol J., Roca-Ferrer J. i wsp, Expression of glucocorticoid receptor alpha- and beta-isotbrms in human cells and tissues. Am. J. Physiol. Cell. Physiol. 2002; 283: C1324-C1331.
47. Leung D.Y.M., Hamid Q., Vottero A. i wsp. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor b. J. Exp. Med. 1997; 186: 1567-1574.
48. Bodwell J.E., Webster J.C., Jewell C.M., Cidlowski J.A., Hu J.M., Munck A. Glucocorticoid receptor phosphorylation: overview, function and cell cycle-dependence. J. Steroid. Biochem. Mol. Biol., 1998; 65: 91-99.
49. Dostert A., Heinzel T. Negative glucocorticoid receptor response elements and their role in glucocorticoid action. Curr. Pharm. Des. 2004; 10: 2807-2816.
50. Kurihara I., Shibata H., Suzuki T. i wsp. Expression and regulation of nuclear receptor coactivators in glucocorticoid action. Mol. Cell. Endocrinol. 2002; 189: 181-189.
51. Hall S.E., Lim S., Witherden I.R. i wsp. Lung type II cell and macrophage annexin I release: differential effects of two gluco-corticoids. Am. J. Physiol. 1999; 276: L114-L121.
52. Heck S., Bender K., Kullmann M., Gottlicher M., Herrlich P., Cato A.C. kB alpha-independent downregulation of NF-κB activity by glucocorticoid receptor. EMBO. J. 1997; 16: 4698-4707.
53. Mittelstadt P.R., Ashwell J.D. Inhibition of AP-1 by the glucocorticoid-inducible protein GILZ. J. Biol. Chem. 2001; 276: 29603-29610.
54. Lasa M., Abraham S.M., Boucheron C., Saklatvala J., Clark A.R. Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol. Cell. Biol. 2002; 22: 7802-7811.
55. Barnes P.J., Adcock I.M., Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur. Respir. J. 2005; 25: 552-563.
56. Reichardt H.M., Tuckermann J.P., Gottlicher M. i wsp, Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J. 2001; 20: 7168-7173.
57. Barnes P.J. Theophylline: new perspectives for an old drug. Am. J. Respir, Crit. Care Med. 2003; 167: B13-818.
58. Ito K., Lim S., Caramori G. i wsp. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression, Proc. Natl. Acad. Sci. USA, 2002; 99: 8921-8926.
59. Cosio B.G., Tsaprouni L., Ito K., Jazrawi E., Adcock I.M., Barnes P.J. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J. Exp. Med. 2004; 200: 689-695.
60. Culpitt S., Maziak W., Loukides S., Keller A., Barnes P.J. Effect of theophylline on induced sputum inflammatory indices in COPD patients. Am. J. Respir. Crit. Care Med. 1997; 157: A797.
61. Barnes P.J. Targeting histone deacetylase 2 in chronic obstructive pulmonary disease treatment. Expert Opin. Ther. Targets, 2005; 9: 1111-1121.
62. Barnes P.J. The role of theophylline in severe asthma. Eur. Respir. Rev. 1996; 6: 154S-159S.
63. Bowler R.P., Barnes P.J., Crapo J.D. The role of oxidative stress in chronic obstructive pulmonary disease. J. COPD 2004; 2: 255-277.
64. Rahman I., Marwick J., Kirkham P. Redox modulation of chromatin remodeling: impact on histone acetylation and deacetylation, NF-κB and proinflammatory gene expression. Biochem. Pharmacol. 2004; 68: 1255-1267.
65. Allegra L., Dal Sasso M., Bovio C., Massoni C., Fonti E., Braga P.C. Human neutrophil oxidative bursts and their in vitro modulation by different N-acetylcysteine concentrations. Arzneimittelforschung 2002; 52: 669-676.
66. De Caro L., Ghizzi A., Costa R., Longo A., Ventresca G.P., Lodola E. Pharmacokinetics and bioavailability of oral acetylcysteine in healthy volunteers. Arzneimittelforschung 1989; 39: 382-386.
67. Santangelo F. Intracellular thiol concentration modulating inflammatory response: influence on the regulation of cell functions through cysteine prodrug approach. Curr. Med. Chem. 2003; 10: 2599-610.
68. Rahman I., MacNee W. Regulation of redox glutathione levels and gene transcription in lung inflammation: therapeutic approaches. Free Radic. Biol. Med. 2000; 28: 1405-1420.
69. Grinberg L., Fibach E., Amer J., Atlas D. N-acetylcysteine amide, a novel cell-permeating thiol, restores cellular glutathione and protects human red blood cells from oxidative stress. Free Radio. Biol. Med. 2005; 38: 136-145.
70. Benrahmoune M., Therond P., Abedinzadeh Z. The reaction of superoxide radical with N-acetylcysteine. Free Radie. Biol. Med. 2000; 29: 775-782.
71. Aruoma O.I., Halliwell B. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic. Biol. Med. 1989; 6: 593-597.
72. Desaki M., Takizawa H., Kasama T., Kobayashi K., Morita Y., Yamamoto K. Nuclear factor-κB activation in siliea-induced interleukin 8 production by human bronchial epithelial cells. Cytokine 2000; 12: 1257-1260.
73. Wuyts W.A., Vanaudenaerde B.M., Dupont L.J., Demedts M.G., Verleden G.M. Involvement of p38 MAPK, JNK, p42/p44 ERK and NF-κB in IL-lbeta-induced chemokine release in human airway smooth muscle cells. Respir. Med. 2003; 97: 811-617.
74. Zafarullah M., Li W.Q., Sylvester J., Ahmad M. Molecular mechanisms of N-acetylcysteine actions. Cell. Mol, Life Sci. 2003; 60: 6-20.
75. Bridgeman M.M., Marsden M., Selby C., Morrison D., MacNee W. Effect of N-acetyl cysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue. Thorax 1994; 49: 670-675.
76. Grandjean E.M., Berthet P., Ruffmann R., Leuenberger P. Efficacy of oral long-term N-acetyleysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin. Ther. 2000; 22: 209-221.